1. A method of treating dermatological disorders, comprising:

administering topically to a subject having said dermatological disorder a therapeutically effective amount of a compound comprising a mono- or diester of an alpha, omega dicarboxylic acid, wherein at least one ester moiety of the said compound comprises a active alcohol moiety, selected from the groups comprising steroid hormones, corticosteroids, vitamin E and vitamin D.

2. The method of claim 1, wherein said compound is applied topically to an affected area.

3. The method of claim 1, wherein said disorder involves inflammation, bacterial and fungal infection, hyperpigmentation, hyperkeratinization, hypertrophy of the stratum corneum, excess sebum secretion, microbial infection, dermatophytoses, or increased conversion of testosterone to dihydrotestosterone.

4. The method of claim 1, wherein said disorder involves aging skin, dry skin, scaly skin, sun damaged skin, oily skin, fine lines and wrinkles, age spots, various hyperpigmented spots, melasma, puffy eyes, acne, redness of the skin, spider veins telangiectasia, atrophic and hypertropic scar, cellulite and obesity.

5. The method of claim 1, wherein said disorder involves a plurality of etiological factors.

6. The method of claim 1, wherein said disorder is selected from the group comprising:

dermatitis, contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, chronic dermatitis of the hands and feet, generalized exfoliative dermatitis, stasis dermatitis, lichen simplex chronicus, bacterial infections, cellulites, acute

lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, staphylococcal scalded skin syndrome, folliculitis, furuncles, hidradenitis sppurativa, carbuncles, paronychial infections, erythrasma, impetigo, fungal infections, dermatophyte infections, yeast infections, viral infections, acne, rosacea, perioral dermatitis, hypertrichosis, hirsutism, alopecia, psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, sunburn, chronic effects of sunlight, photosensitivity, hypopigmentation, vitiligo, albinism, postinflammatory hypopigmentation, hyperpigmentation, melasma (chloasma), drug-induced hyperpigmentation, postinflammatory hyperpigmentation, disorders of cornification, ichthyosis, keratosis pilaris and eczema

7. The method of claim 1, wherein the alpha, omega dicarboxylic acid comprises 6 to 14, preferably 8 to 10, carbon atoms in its carbon chain backbone.

8. The method of claim 1, wherein said alpha, omega dicarboxylic acid comprises azelaic acid.

9. The method of claim 1, wherein the alpha, omega dicarboxylic acid carbon chain backbone is unsaturated.

10. The method of claim 1, wherein the alpha, omega dicarboxylic acid moiety is linked to a hydrocarbon substituent.

11. The method of claim 1, wherein the alpha, omega dicarboxylic acid moiety is substituted by alkyl, aryl, alkenyl or benzyl groups.

12. The method of claim 1, wherein said alpha, omega dicarboxylic acid is selected from the group consisting of adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, 1,11-undecanedioic acid, 1,12-dodecanedioic acid, 1,13-tridecanedioic acid and 1,14-tetradecanedioic acid.

13. A compound for the treatment of a skin disorder, comprising an alpha, omega dicarboxylic acid, covalently linked through an ester bond with at least one active alcohol moiety, selected from the group comprising steroid hormones, corticosteroids, vitamin E and vitamin D.

14. The compound of claim 13, wherein the alpha, omega dicarboxylic acid comprises 6 to 14, preferably 8 to 10, carbon atoms in its carbon chain backbone.

15. The compound of claim 13, wherein said alpha, omega dicarboxylic acid is selected from the group consisting of adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, 1,11-undecanedioic acid, 1,12-dodecanedioic acid, 1,13-tridecanedioic acid and 1,14-tetradecanedioic acid.

16. The compound of claim 13, wherein said alpha, omega dicarboxylic acid comprises azelaic acid.

17. The compound of claim 13, wherein the alpha, omega dicarboxylic acid carbon chain backbone is unsaturated.

18. The method of claim 17, wherein the backbone comprises about one to three double bonds.

19. The compound of claim 13, wherein the alpha, omega dicarboxylic acid moiety is linked to a hydrocarbon substituent.

20. The compound of claim 13, wherein the alpha, omega dicarboxylic acid moiety is substituted by alkyl, aryl, alkenyl or benzyl groups.

21. A pharmaceutical or cosmetic composition, comprising

a therapeutically effective amount of a compound, comprising an alpha, omega dicarboxylic acid covalently linked through an ester bond with at least one active alcohol moiety, selected from the group comprising steroid hormones, corticosteroids, vitamin E and vitamin D

and a pharmaceutically or cosmetically acceptable carrier.

22. The pharmaceutical or cosmetic composition of claim 21, wherein the alpha, omega dicarboxylic acid comprises 6 to 14, preferably 8 to 10, carbon atoms in its carbon chain backbone.

23. The pharmaceutical or cosmetic composition of claim 21, wherein said alpha, omega dicarboxylic acid is selected from the group consisting of adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, 1,11-undecanedioic acid, 1,12-dodecanedioic acid, 1,13-tridecanedioic acid and 1,14-tetradecanedioic acid.

24. The pharmaceutical or cosmetic composition of claim 21, wherein said alpha, omega dicarboxylic acid comprises azelaic acid.

25. The pharmaceutical or cosmetic composition of claim 21, wherein the alpha, omega dicarboxylic acid carbon chain backbone is unsaturated.

26. The pharmaceutical or cosmetic composition of claim 25, wherein the backbone comprises about one to three double bonds.

27. The pharmaceutical or cosmetic composition of claim 21, wherein the alpha, omega dicarboxylic acid moiety is linked to a hydrocarbon substituent.

28. The pharmaceutical or cosmetic composition of claim 21, wherein the alpha, omega dicarboxylic acid moiety is substituted by alkyl, aryl, alkenyl or benzyl groups.

29. The composition of claim 21, wherein said therapeutically effective amount of said compound comprises an amount effective to treat a dermatological or cosmetic disorder.

30. The composition of claim 29, wherein said disorder involves inflammation, bacterial and fungal infection, hyperpigmentation, hyperkeratinization, hypertrophy of the stratum corneum, excess sebum secretion, microbial infection, dermatophytoses, or increased conversion of testosterone to dihydrotestosterone.

31. The composition of claim 29, wherein said disorder is selected from the group, comprising aging skin, dry skin, scaly skin, sun damaged skin, oily skin, fine lines and wrinkles, age spots, various hyperpigmented spots, melasma, puffy eyes, acne, redness of the skin, spider veins telangiectasia, atrophic and hypertropic scar, cellulite and obesity.

32. The composition of claim 29, wherein said disorder is selected from the group comprising:

dermatitis, contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, chronic dermatitis of the hands and feet, generalized exfoliative dermatitis, stasis dermatitis, lichen simplex chronicus, bacterial infections, cellulites, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, staphylococcal scalded skin syndrome, folliculitis, furuncles, hidradenitis sppurativa, carbuncles, paronychial infections, erythrasma, impetigo, fungal infections, dermatophyte infections, yeast infections, viral infections, acne, rosacea, perioral dermatitis, hypertrichosis, hirsutism, alopecia, psoriasis, pityriasis rosea, lichen

planus, pityriasis rubra pilaris, sunburn, chronic effects of sunlight, photosensitivity, hypopigmentation, vitiligo, albinism, postinflammatory hypopigmentation, hyperpigmentation, melasma (chloasma), drug-induced hyperpigmentation, postinflammatory hyperpigmentation, disorders of cornification, ichthyosis, keratosis pilaris and eczema

33. The composition of claim 21,wherein said compound is functional to release a plurality of dermatologically-active compounds when delivered to a target site of the skin.

34. The composition of claim 21, wherein said composition is in a form selected from the group consisting of liquid, solution, lotion, cream, paste, emulsion, gel, soap bar, foam, spray and aerosol.